Breakthrough combo therapy shows promise against deadly stomach cancers
NCT ID NCT03813784
Summary
This large study tested whether adding two newer drugs (camrelizumab and apatinib) to standard chemotherapy works better than chemotherapy alone for advanced stomach cancer. The trial involved 885 patients who hadn't received previous treatment for their advanced cancer. Researchers compared survival and side effects between the two treatment approaches to see if the combination could better control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital, Peking University
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.